Horgen

Researchers are evaluating if the medidux132 smartphone app can improve care after discharge for adults admitted to Acute Admission Units (AAU) with non-urgent health complaints like cough, back pain, or abdominal discomfort. The study focuses on adults aged 18 and older who fall under Emergency Severity Index groups 4 or 5. The main goal is to see if the app can lower the chances of readmission, emergency hospital visits, or medical consultations within 7 days after their initial admission. Participants are divided into two groups: one uses the medidux132 app to track symptoms and vital signs daily for 7 days after leaving the hospital, while the other group receives standard care without the app. The app provides automated reminders and guidance to help users manage their symptoms and know when to seek medical help. All participants have follow-up consultations on day 7 and day 28 to check on symptom progress and any healthcare visits. During the study, participants will report their symptoms and vital signs through the app or standard care methods. Researchers will monitor readmissions, emergency hospitalizations, and other medical visits within 7 days after discharge. Follow-up visits at day 7 and day 28 will assess health status and any use of healthcare services. The study helps understand if using a mobile health app can support better post-discharge management for AAU patients.

Researchers are studying children and adolescents in Switzerland who visit doctors for recurrent wheezing, coughing, and breathing problems related to exercise or sleep. The Swiss Paediatric Airway Cohort (SPAC) aims to understand different types of respiratory issues, their outcomes, diagnosis, and treatment. This long-term study collects real-life data from patients seen in 10 clinics across Switzerland and seeks to build a platform for future research and healthcare improvements. Participants are patients aged 0 to 16 years referred to pediatric pulmonary outpatient clinics for respiratory symptoms. Families receive detailed questionnaires at the start, and follow-ups include monthly online questionnaires during the first year and yearly postal questionnaires afterward. No tests are done specifically for the study; only clinically needed examinations such as lung function, allergy, blood, or bronchial challenge tests are performed as part of routine care. Families complete questionnaires about symptoms, treatments, and risk factors, while medical records provide additional clinical data and test results. The study tracks outcomes like wheezing, coughing (apart from colds), exercise-induced breathing difficulties, and lung function over one year. Data collection is supported by visits to clinics and ongoing follow-up, allowing researchers to monitor health changes and treatment responses over time. The total participation duration varies with annual follow-ups continuing beyond the first year.

Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that arise from the neuroendocrine system in the gastrointestinal tract and pancreas. This registry study aims to better understand these tumors by collecting detailed clinical information from patients diagnosed with GEP-NETs in Switzerland. Since limited knowledge exists about the biology and treatment of these tumors, the study focuses on gathering data to improve understanding and management strategies. Patients with a confirmed diagnosis of neuroendocrine tumors from any location who agree to participate will have their information entered prospectively into a secure, anonymized database. Data collection involves visits from study nurses to healthcare centers, where patient files are reviewed and information is recorded. There are no specific treatments assigned by this registry; instead, it tracks various treatment approaches used in Switzerland. Participants contribute data that includes tumor types, treatments received, and outcomes such as mortality and hospitalization rates. The study reviews and evaluates this information regularly to identify patterns and assess patient outcomes over time. The main outcome measured is tumor-related mortality every five years, helping to monitor long-term effects. This registry allows for improved knowledge sharing across hospitals and practitioners in Switzerland to enhance care for patients with neuroendocrine tumors.